Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura

OBJECTIVE: To investigate the efficacy and safety of rituximab (RTX) as first-line treatment of acquired thrombotic thrombocytopenic purpura (aTTP). METHODS: Twenty-five patients with acute aTTP and/or severe a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Int Med Res
Hlavní autoři: Chen, Haifei, Fu, Ailin, Wang, Jing, Wu, Tianqin, Li, Zhengyang, Tang, Jieqing, Shen, Hongshi, Zhu, Jingjing, Li, Jie, Zhu, Qian, Qing, Longmei
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2017
Témata:
Clinical Note
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5536423/
https://ncbi.nlm.nih.gov/pubmed/28639502
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0300060517695646
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky